Cargando…

Plant Source Derived Compound Exhibited In Silico Inhibition of Membrane Glycoprotein In SARS-CoV-2: Paving the Way to Discover a New Class of Compound For Treatment of COVID-19

SARS-CoV-2 is the virus responsible for causing COVID-19 disease in humans, creating the recent pandemic across the world, where lower production of Type I Interferon (IFN-I) is associated with the deadly form of the disease. Membrane protein or SARS-CoV-2 M proteins are known to be the major reason...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahanta, Saurov, Naiya, Tufan, Biswas, Kunal, Changkakoti, Liza, Mohanta, Yugal Kishore, Tanti, Bhaben, Mishra, Awdhesh Kumar, Mohanta, Tapan Kumar, Sharma, Nanaocha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022603/
https://www.ncbi.nlm.nih.gov/pubmed/35462888
http://dx.doi.org/10.3389/fphar.2022.805344
_version_ 1784690122548051968
author Mahanta, Saurov
Naiya, Tufan
Biswas, Kunal
Changkakoti, Liza
Mohanta, Yugal Kishore
Tanti, Bhaben
Mishra, Awdhesh Kumar
Mohanta, Tapan Kumar
Sharma, Nanaocha
author_facet Mahanta, Saurov
Naiya, Tufan
Biswas, Kunal
Changkakoti, Liza
Mohanta, Yugal Kishore
Tanti, Bhaben
Mishra, Awdhesh Kumar
Mohanta, Tapan Kumar
Sharma, Nanaocha
author_sort Mahanta, Saurov
collection PubMed
description SARS-CoV-2 is the virus responsible for causing COVID-19 disease in humans, creating the recent pandemic across the world, where lower production of Type I Interferon (IFN-I) is associated with the deadly form of the disease. Membrane protein or SARS-CoV-2 M proteins are known to be the major reason behind the lower production of human IFN-I by suppressing the expression of IFNβ and Interferon Stimulated Genes. In this study, 7,832 compounds from 32 medicinal plants of India possessing traditional knowledge linkage with pneumonia-like disease treatment, were screened against the Homology-Modelled structure of SARS-CoV-2 M protein with the objective of identifying some active phytochemicals as inhibitors. The entire study was carried out using different modules of Schrodinger Suite 2020-3. During the docking of the phytochemicals against the SARS-CoV-2 M protein, a compound, ZIN1722 from Zingiber officinale showed the best binding affinity with the receptor with a Glide Docking Score of −5.752 and Glide gscore of −5.789. In order to study the binding stability, the complex between the SARS-CoV-2 M protein and ZIN1722 was subjected to 50 ns Molecular Dynamics simulation using Desmond module of Schrodinger suite 2020-3, during which the receptor-ligand complex showed substantial stability after 32 ns of MD Simulation. The molecule ZIN1722 also showed promising results during ADME-Tox analysis performed using Swiss ADME and pkCSM. With all the findings of this extensive computational study, the compound ZIN1722 is proposed as a potential inhibitor to the SARS-CoV-2 M protein, which may subsequently prevent the immunosuppression mechanism in the human body during the SARS-CoV-2 virus infection. Further studies based on this work would pave the way towards the identification of an effective therapeutic regime for the treatment and management of SARS-CoV-2 infection in a precise and sustainable manner.
format Online
Article
Text
id pubmed-9022603
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90226032022-04-22 Plant Source Derived Compound Exhibited In Silico Inhibition of Membrane Glycoprotein In SARS-CoV-2: Paving the Way to Discover a New Class of Compound For Treatment of COVID-19 Mahanta, Saurov Naiya, Tufan Biswas, Kunal Changkakoti, Liza Mohanta, Yugal Kishore Tanti, Bhaben Mishra, Awdhesh Kumar Mohanta, Tapan Kumar Sharma, Nanaocha Front Pharmacol Pharmacology SARS-CoV-2 is the virus responsible for causing COVID-19 disease in humans, creating the recent pandemic across the world, where lower production of Type I Interferon (IFN-I) is associated with the deadly form of the disease. Membrane protein or SARS-CoV-2 M proteins are known to be the major reason behind the lower production of human IFN-I by suppressing the expression of IFNβ and Interferon Stimulated Genes. In this study, 7,832 compounds from 32 medicinal plants of India possessing traditional knowledge linkage with pneumonia-like disease treatment, were screened against the Homology-Modelled structure of SARS-CoV-2 M protein with the objective of identifying some active phytochemicals as inhibitors. The entire study was carried out using different modules of Schrodinger Suite 2020-3. During the docking of the phytochemicals against the SARS-CoV-2 M protein, a compound, ZIN1722 from Zingiber officinale showed the best binding affinity with the receptor with a Glide Docking Score of −5.752 and Glide gscore of −5.789. In order to study the binding stability, the complex between the SARS-CoV-2 M protein and ZIN1722 was subjected to 50 ns Molecular Dynamics simulation using Desmond module of Schrodinger suite 2020-3, during which the receptor-ligand complex showed substantial stability after 32 ns of MD Simulation. The molecule ZIN1722 also showed promising results during ADME-Tox analysis performed using Swiss ADME and pkCSM. With all the findings of this extensive computational study, the compound ZIN1722 is proposed as a potential inhibitor to the SARS-CoV-2 M protein, which may subsequently prevent the immunosuppression mechanism in the human body during the SARS-CoV-2 virus infection. Further studies based on this work would pave the way towards the identification of an effective therapeutic regime for the treatment and management of SARS-CoV-2 infection in a precise and sustainable manner. Frontiers Media S.A. 2022-04-07 /pmc/articles/PMC9022603/ /pubmed/35462888 http://dx.doi.org/10.3389/fphar.2022.805344 Text en Copyright © 2022 Mahanta, Naiya, Biswas, Changkakoti, Mohanta, Tanti, Mishra, Mohanta and Sharma. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Mahanta, Saurov
Naiya, Tufan
Biswas, Kunal
Changkakoti, Liza
Mohanta, Yugal Kishore
Tanti, Bhaben
Mishra, Awdhesh Kumar
Mohanta, Tapan Kumar
Sharma, Nanaocha
Plant Source Derived Compound Exhibited In Silico Inhibition of Membrane Glycoprotein In SARS-CoV-2: Paving the Way to Discover a New Class of Compound For Treatment of COVID-19
title Plant Source Derived Compound Exhibited In Silico Inhibition of Membrane Glycoprotein In SARS-CoV-2: Paving the Way to Discover a New Class of Compound For Treatment of COVID-19
title_full Plant Source Derived Compound Exhibited In Silico Inhibition of Membrane Glycoprotein In SARS-CoV-2: Paving the Way to Discover a New Class of Compound For Treatment of COVID-19
title_fullStr Plant Source Derived Compound Exhibited In Silico Inhibition of Membrane Glycoprotein In SARS-CoV-2: Paving the Way to Discover a New Class of Compound For Treatment of COVID-19
title_full_unstemmed Plant Source Derived Compound Exhibited In Silico Inhibition of Membrane Glycoprotein In SARS-CoV-2: Paving the Way to Discover a New Class of Compound For Treatment of COVID-19
title_short Plant Source Derived Compound Exhibited In Silico Inhibition of Membrane Glycoprotein In SARS-CoV-2: Paving the Way to Discover a New Class of Compound For Treatment of COVID-19
title_sort plant source derived compound exhibited in silico inhibition of membrane glycoprotein in sars-cov-2: paving the way to discover a new class of compound for treatment of covid-19
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022603/
https://www.ncbi.nlm.nih.gov/pubmed/35462888
http://dx.doi.org/10.3389/fphar.2022.805344
work_keys_str_mv AT mahantasaurov plantsourcederivedcompoundexhibitedinsilicoinhibitionofmembraneglycoproteininsarscov2pavingthewaytodiscoveranewclassofcompoundfortreatmentofcovid19
AT naiyatufan plantsourcederivedcompoundexhibitedinsilicoinhibitionofmembraneglycoproteininsarscov2pavingthewaytodiscoveranewclassofcompoundfortreatmentofcovid19
AT biswaskunal plantsourcederivedcompoundexhibitedinsilicoinhibitionofmembraneglycoproteininsarscov2pavingthewaytodiscoveranewclassofcompoundfortreatmentofcovid19
AT changkakotiliza plantsourcederivedcompoundexhibitedinsilicoinhibitionofmembraneglycoproteininsarscov2pavingthewaytodiscoveranewclassofcompoundfortreatmentofcovid19
AT mohantayugalkishore plantsourcederivedcompoundexhibitedinsilicoinhibitionofmembraneglycoproteininsarscov2pavingthewaytodiscoveranewclassofcompoundfortreatmentofcovid19
AT tantibhaben plantsourcederivedcompoundexhibitedinsilicoinhibitionofmembraneglycoproteininsarscov2pavingthewaytodiscoveranewclassofcompoundfortreatmentofcovid19
AT mishraawdheshkumar plantsourcederivedcompoundexhibitedinsilicoinhibitionofmembraneglycoproteininsarscov2pavingthewaytodiscoveranewclassofcompoundfortreatmentofcovid19
AT mohantatapankumar plantsourcederivedcompoundexhibitedinsilicoinhibitionofmembraneglycoproteininsarscov2pavingthewaytodiscoveranewclassofcompoundfortreatmentofcovid19
AT sharmananaocha plantsourcederivedcompoundexhibitedinsilicoinhibitionofmembraneglycoproteininsarscov2pavingthewaytodiscoveranewclassofcompoundfortreatmentofcovid19